Johnson and Johnson successfully applied for a patent extension on bedaquiline; however, in a big win for LMI countries, the company has decided not to enforce its patent, allowing generic producers to manufacture the drug. Additionally, J&J has reduced the price of bedaquiline for South Africa by around 40%, making it more affordable for the country. J&J’s reversal of its past decisions regarding bedaquiline was prompted by an investigation of the company’s pricing policies led by the South African government. Learn more here.
top of page
Recent Posts
See AllThe Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...
350
The positive EndTB-Q trial results were shared at the Union conference. They showed that a BCDL regimen is successful in treating less...
190
John Green’s new book Everything is Tuberculosis is scheduled to be published in Spring 2025. The novel laces the experiences of Henry, a...
240
bottom of page
Comments